Bactiguard Holding AB (CHIX:BACTBS) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BACTBS Bactiguard Holding AB CHIX:BACTBS
56 GF Score
Price kr128.60
GF Value kr266.73
! 2 Warning Signs
View Full Analysis

What is Bactiguard Holding AB Defensive Interval Ratio?

CHIX:BACTBS
56GF Score
Bactiguard Holding AB CHIX:BACTBS
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?

Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued. The current stock price of kr128.60 is trading 51.8% below its estimated GF Value™ of kr266.73.

Key valuation signals for CHIX:BACTBS:

  • Defensive Interval Ratio:
  • GF Value™: kr266.73 vs. price of kr128.60 (51.8% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bactiguard Holding AB Business Description

Other Exchanges BACTI B:Sweden5JE:Germany
Address Vasagatan 11, Stockholm, SWE, 111 20
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
56GF Score

Get the complete analysis for CHIX:BACTBS

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr128.60
Price
kr266.73
GF Value